H. Lundbeck A/S
HLUN-A
株式のランク
#3037
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
株価
$7.29
時価総額
$6.07B
変化（1日）
1.77%
変化（1年）
31.48%
国
DK
取引 H. Lundbeck A/S (HLUN-A)
カテゴリー
Healthcare
H. Lundbeck A/S（HLUN-A）の営業利益率
October 2026 時点の営業利益率 TTM: 27.21%
H. Lundbeck A/S の最新の財務報告と株価によると、現在の営業利益率（TTM）は 27.21% です。2024 年末時点では 14.86% でした。
H. Lundbeck A/S の営業利益率の履歴（2004 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 27.21% | 4.45% |
| 2025 | 26.05% | 75.30% |
| 2024 | 14.86% | -7.41% |
| 2023 | 16.05% | 2.69% |
| 2022 | 15.63% | 26.76% |
| 2021 | 12.33% | 9.50% |
| 2020 | 11.26% | -45.84% |
| 2019 | 20.79% | -29.91% |
| 2018 | 29.66% | 15.95% |
| 2017 | 25.58% | 74.49% |
| 2016 | 14.66% | -132.77% |
| 2015 | -44.73% | -6,144.59% |
| 2014 | 0.74% | -92.94% |
| 2013 | 10.48% | -5.84% |
| 2012 | 11.13% | -47.50% |
| 2011 | 21.20% | -6.77% |
| 2010 | 22.74% | 9.38% |
| 2009 | 20.79% | -0.24% |
| 2008 | 20.84% | -15.08% |
| 2007 | 24.54% | 26.82% |
| 2006 | 19.35% | -19.11% |
| 2005 | 23.92% | -8.84% |
| 2004 | 26.24% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 62.34% | -97.71% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -98.91% |
HK
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。